INTROD UCTIO
Over the past several years, a number of ca rd io vasc u lar preparations have become widely used in psychiatry. For example , propranol ol , int roduced for its anti-angina l properties, is now used fo r stage-fright, lithium tremor a nd ne uroleptic induced a kath isia ( 1, 2) . Calcium channel b lockers are e xpecte d to pro ve use ful in the treatment of bi pol a r affective d isorders (3, 4) .
C lonidine exemplifies the rapidity and variety with whi ch a ca rdiovascu lar agent has been applied to psychiatric syndromes. Clonidine , a ce n tra lly acting anti-h ypertensive drug with both alpha-l and alpha-2 ad re ne rgic agonistic properties, has a lready been used in the treatment o f na rcotic with d ra wal, benzodiazepine withdrawal , Tourette's syndrom e , a ka t h isia, d epressio n , ch r o n ic schizophrenia and acute mania, as well as in tardive d yskinesia ( 1, 5, 6) .
T he therapeutic effectiveness of clonidine in tardive d yskinesia was in itiall y reported by Freedma n a nd co -workers and by Nishikawa and co -wo r ke rs (7, 8) . Tardive dyskinesia is a term applied to a group of involuntary mov eme nt disorders usu all y involving t he oro-facial region , but also affecting lim bs and trunk. This disorder, on average reversible in ov e r one-third of all patien ts in whom ne uroleptics a re d iscontinued (9) , is a persistent neurologic co m p lication induced b y longterm neuroleptic treatment. Ni shikawa a nd co-wor ke rs trea ted 29 such patients wit h c1onidine; results at 4 yea rs follow up showed th a t 75 percent showed at least moderate improvement; full resolution occu r red in 50 percent of the cases (10) . Onset of improvement oc curred wit h in 3 to 7 d a ys of initiating clonidine treatmen t. The present co m m u n ica tio n reports an additional case in which videotapes documented th e movement di sorder before and d u r ing clo n idine treatment. Abrupt cessation of clonidine resu lted in e n ha nced dys kinetic mo vemen ts.
CASE REPO RT
The patient is a 29 yea r old white single stu den t admitted volunta r ily to a psychiatric hospita l after three da ys of auditory a nd visual hallucin ati ons and vague fe e lings of depersonalization . The patient's fir st co n tact with psychia tr y occurred 5 years previous ly wh en h e was diagnosed as being " psyc hot ica lly depressed" with symptoms of d epe rso na liza t io n a nd d erealization. The prese n t admission was his fifth psychiatric hospitalization. He had been treated wit h a variety of antipsychotics; three yea rs prior to admission he was stabili zed on 10 mg of thiothixene per day. This was discontinued one yea r prior to ad m ission. However, three months prior to admission he was restarted o n th iothi xe ne at doses ranging from 15 mg to 40 mg per da y as a result of re-emergence of psychotic symptoms. The case was further complicated by th e prese nce of complex partial seizures, which were reported to have occurred 2-3 t imes a week; electroencephalogram showed paroxsymal bursts of diffuse th eta waves.
According to his mother, abnormal movements o f th e upper ex tremities, facial grimacing, and tic-like movements had become obvious six months p ri o r to admission. The movements were continuous and not se izu re related. O nce the diagnosis of tardive dyskinesia was suspected, the doses o f thiothixene were gradually decreased. The patient had abused numerous substances, includi ng coc aine , LSD, alcohol and marijuana since adolescence. There was no curre nt substance abuse. It is important to note that the patient's brother was also tak in g antipsychotic medication. He also exhibited a movement disorder ch a rac te r ized by d ystonic posturing, but refused further neuropsychiatri c e va lua t io n of th ese movements.
Initiall y the patient e xh ib ite d a mildly constricted a ffect with d yspho ri c mood. His speech was coherent, although digressive . H e d escribed fee lings of derealization and depersonalization; there were no hallucinations o r di sruptive behaviors. The patient's general ph ysical and neurologi c exam was no r ma l (asid e from abnormal movements). Neithe r h ypotonia nor in coordi nati o n was present. He was noted to have co ntin uo us ste reo ty ped in vo lu n tary choreoa thetoid movements in the upper extrerneties including g r imac ing a nd bucco-l ingual masticatory movements. Blood chemistries were within normal limits, in clu di ng normal th yroid function tests. A magnetic resonance sca n was no rmal.
Repeat electroencephalograph y showed generalized th eta wave slowing. Differential diagnostic possibilities that were ruled out included Huntingto n 's chorea, Tourettes syndrome, amph etamine intoxicati on , brain tumo r and torsion dystonia. The consulting neurologist co n fir med th e diagnosis of tard ive d yskinesia. The consultant also recommended an e m p ir ica l tri al of a nticonvulsants because the psychic symptomatology in conjunction with th e nonspecific EEG abnormalities were so suggestive of complex partial seizures. The patient was thus treated with valproic acid.
The patient's thiothixene was gradually reduced to 5 mg once dail y. A t this point the patient's movements were videotaped. Clonidine 0.1 milligram twice daily was initiated. Thereafter on every second da y, clonidine was in creased by a tenth of a milligram and thiothixene was decreased by one milligram a day. The dosage of clonidine was stabilized at 0.5 milligrams a da y, in part beca use postural hypotension developed at this point. Thiothixene was th en di scon t inued . After three da ys on this dosage , repeat videotaping a nd a repeat A I MS rating was done. Significant clinical improvement was noted. T a b le One shows the blind ratings by two observers and AIMS scores (11) (d on e by two treat ing ph ysician s) ob tained befo re t reatment was initiated, after three da ys of treatment and after 10 days of treatment. The patient was dis charged, but rehospita lized three weeks la te r after having abruptly discontinued all hi s medica t io ns. The "after ce ssation" co lumn on Table I shows the AIMS ratin gs for his movement disorder at that time. H e refused to be videotaped, but th e trea ti ng p h ysicians rated his movements as having returned to pre-treatment le vel s of severity .
T he patient refused furt her treatment of h is movement di sorde r or clonidine treatment. H o we ve r , he did continue to take valproi c ac id whi ch had been started for his complex partial seizures, a total of 12 50 m illigra ms in divided doses.
DISCUSSION
Accurate d iagnosis is the first problem in any study of th e treatment of tardive d yskinesia. T he d iffe r e n tial diagnosis is extensive and includes Huntington's chorea, Tourette's syndrome, L-dopa induced chorea , se n ile chorea, Wi lson's d isease, torsion d ystonia, viral encephalitis and amph e tamine intoxication. Also, in the absence of a history of exposure to a n ti-psychot ic medica tio n or neuroleptics used as antiemetics, there does not appear to be , as yet, any biochemica l or clin ical way to establish whether a choreiform o r d ystonic movemen t is " ta rdive" or is a refl ectio n of a primary neurologic disorder ( 12) . A furt her complication is that on the average tardive d yskinesi a is rev e rsible in only a third of all patients in whom neurolept ics are dis continued a nd tends to T A BL E 1. persist at an even level of severity in the remaining two-thirds of the patients (9) . In this case, the presence of an affected sibling and EEG a bnormalities caused us to suspect the possibility of a primary rath er than drug-re la ted movement disorder. However, consultants viewing th e vid eotapes ha ve diagnosed tardive dyskinesia uniformly. We also considered the possibil it y that the patient's AIMS scores improved because of neurolepti c withdraw al rather th a n the use of clonidine; however, the rapid time course of impro vement a nd th e return of abnormal movements once clonidine was withdrawn argue against th is explanation .
Ratings of Patient's Movement
Tardive d yskinesia is thought to result from ch r o n ic block ade of receptors by neuroleptics leading to supersensitization of post synaptic striatal d opam ine receptors (13) . Neuroleptics block dopamine receptors thus pre ventin g dopamine from acting on post-synaptic neurons. The post-synapti c ce ll responds to this blockade by making new dopamine receptors, after whi ch th e ce ll becomes supersensitive to dopamine. This supersensitivity is said to relate to tard ive d yskinesia; however, nothing in this hypothesis explains wh y onl y a few patie nts subjected to long term dopamine receptor block ade d ev elop d yskinetic movements. The hypothesis does predict, however, that wh en receptors are unblocked, for example when neuroleptics are discontinued, post-syn ap tic cells will have an increased response and choreiform or dystonic mov emen ts will appear or increase. This is consistent with clinical observations, su ch as t he very typical onset after discontinuation of medication (14, 15) , as occu r red in this case. If doses of neuroleptics are increased, the new receptors are block ed a nd tardive dyskinesia will abate temporarily.
A more recent hypothesis proposes that noradrenergic as well as d opam inergic overactivity is important in tardive dyskinesia (10) . Clonidine in lo w d oses appears to have anti-noradrenergic effects reducing noradrenergi c fu nction by stimulating pre-synaptic noradrenergic neurons, which ultimatel y do wn -regulates th e noradrenergic axis as receptors decrease. The doses of clonidin e used in this study and by Nishikawa and coworkers (10) were com parab le to lo w d oses used in the treatment of h ypertension. Similarly, the three da y delay in o nset and in improvement of tardive dyskinesia after clonidine was started pa rall e ls the one to three day interval before anti-h ypertensive effects are seen wh e n clonidine is used for hypertension . These parallels suggest that clonidin e ma y act in tardive dyskinesia, as has been postulated for its action in h ypertension , by down-regulating noradrenergic transmission.
CONCLUSION
Previous reports indicate that over fift y percent of cases of tardi ve d yski nesia respond with improvement to treatment with th e alpha noradrenergic agonist, clonidine. This report adds another case in which both rapid improvement on initiation and rapid exacerbation on discontinuation o f clonid ine treatment were documented. The postulated mechanism of acti on of c1onid-ine-down-regulation of noradrenergic activity by decreasing fu nc t io na l receptor supersensitivity-meshes with the postulated mechanism fo r tardi ve dysk inesia, receptor supersensitivity. Clonidine has an advantag e ov e r so me o ther agents used to treat tardive dyskinesia, in that it has few sid e e ffec ts. Postural hypotension , the major side effect in our experience , usuall y ca n be con trolled by stabilizing the dosage, as in this case, because e ven low dosages a re effec tive in decreasing abnormal movements.
Discontinuation of neuroleptics or lowering th e dosage as much as clinically possible remains the mainstay of treatment of tardive d ysk in esia. T h is cas e illustrates the importance of some of the measures recomm ended for pre ve nti on of tardive d yskinesia: 1) use of neuroleptics only wh en th ere is a specific indication and 2) th e need to co nsid e r dis continuation of neuroleptics when target symptoms do not respond after six months.
However, as in this case, there is a role for treatments whi ch reduce t he se ve r ity of the movement disorder, even when withdrawal of neuroleptics is the major intervention . Even in those patients who respond to neuroleptic withdrawal, abnormal movements ma y persist.
Because tardive dyskinesia has a high prevalence (15-20 % of those ex posed to a neuroleptic agent for more than one year) and a high incidence (2-5% fo r the first few years of neuroleptic maintenance) (16) , there is need fo r mo re research on treatment methods in this disorder. No treatm ent to date uniform ly benefits d yskinesias in all patients (17) . The work to date with clo n id ine indicat es that finding effective new treatments ca n also give clu es as to the ba sic bi ol ogy o f the disorder.
